Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)

Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)

• Drug: ticagrelor monothearpy after first 3 months dual therapy

The sum of major adverse cardiac and cerebrovaascular event(MACCE) and bleeding event(BARC score)

Major adverse cardiac and cerebrovaascular event(MACCE) includes 1)all-cause motality, 2) acute MI, 3)cerebrovascular event, 4)stent thrombosis

The number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).

type 3a: Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding, type 3b: Overt bleeding plus hemoglobin drop < 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents, type 3c: Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision, type 5a: Probable fatal bleeding, type 5b: Definite fatal bleeding (overt or autopsy or imaging confirmation in accordance with BARC Definitions

1. All-cause mortality :Individual component of MACCE
2. Acute MI :Individual component of MACCE
3. Cerebrovascular event :Individual component of MACCE
4. Stent thrombosis :Definite or probable stent thrombosis defined by Academic Research Consortium (ARC)
5. Bleeding :Bleeding Academic Research Consortium (BARC) type 3 or 5